Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Body

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Current Opinion in Oncology|April 27, 2011
New developments for treatment and prevention of bone metastasesJean-Jacques Body
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Breast cancer: bisphosphonate therapy for metastatic bone diseaseJean-Jacques Body
The Oncologist|April 27, 2005
Bisphosphonate safety and tolerabilityJean-Jacques Body
Breast (Edinburgh, Scotland)|December 9, 2003
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesionsJean-Jacques Body
Cancer|January 28, 2003
Effectiveness and cost of bisphosphonate therapy in tumor bone diseaseJean-Jacques Body
La Revue Du Praticien|March 11, 2004
[How to treat tumor-induced hypercalcemia]Jean-Jacques Body
Supportive Cancer Therapy|July 18, 2008
The risk of cumulative renal effects of intravenous bisphosphonatesJean-Jacques Body
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Bisphosphonates for care and cureJean-Jacques Body
Bonekey Reports|June 18, 2014
Aromatase inhibitors-induced bone loss in early breast cancerJean-Jacques Body
Expert Opinion on Pharmacotherapy|April 2, 2003
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosisJean-Jacques Body
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Current Opinion in Oncology|April 27, 2011
New developments for treatment and prevention of bone metastasesJean-Jacques Body
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Breast cancer: bisphosphonate therapy for metastatic bone diseaseJean-Jacques Body
The Oncologist|April 27, 2005
Bisphosphonate safety and tolerabilityJean-Jacques Body
Breast (Edinburgh, Scotland)|December 9, 2003
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesionsJean-Jacques Body
Cancer|January 28, 2003
Effectiveness and cost of bisphosphonate therapy in tumor bone diseaseJean-Jacques Body
La Revue Du Praticien|March 11, 2004
[How to treat tumor-induced hypercalcemia]Jean-Jacques Body
Supportive Cancer Therapy|July 18, 2008
The risk of cumulative renal effects of intravenous bisphosphonatesJean-Jacques Body
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Bisphosphonates for care and cureJean-Jacques Body
Bonekey Reports|June 18, 2014
Aromatase inhibitors-induced bone loss in early breast cancerJean-Jacques Body
Expert Opinion on Pharmacotherapy|April 2, 2003
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosisJean-Jacques Body
Pageof 14